Mochida Pharmaceutical Co (TSE:4534) Beneish M-Score: -1.75 (As of Jun. 26, 2026)


TSE:4534 Mochida Pharmaceutical Co Ltd TSE:4534
70 GF Score
Price 円3,140.00
GF Value 円3,695.27
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Mochida Pharmaceutical Co Beneish M-Score?

Mochida Pharmaceutical Co TSE:4534 -2.94% 70 Beneish M-Score is -1.75 as of Jun. 26, 2026. GuruFocus rates TSE:4534 with a GF Score™ of 70/100 and a GF Value™ of 円3,695.27 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 911 Drug Manufacturers companies, Mochida Pharmaceutical Co ranks worse than 85.73% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.75 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Mochida Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

TSE:4534' s Beneish M-Score Range Over the Past 10 Years
Min: -2.71   Med: -2.4   Max: -1.75
Current: -1.75

During the past 13 years, the highest Beneish M-Score of Mochida Pharmaceutical Co was -1.75. The lowest was -2.71. And the median was -2.40.


Mochida Pharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Mochida Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mochida Pharmaceutical Co Beneish M-Score Chart

Mochida Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.34 -2.60 -1.85 -2.52 -1.75

Mochida Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.52 0.00 0.00 0.00 -1.75

TSE:4534 vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mochida Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mochida Pharmaceutical Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mochida Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Mochida Pharmaceutical Co's Beneish M-Score falls into.


TSE:4534
70GF Score
Mochida Pharmaceutical Co Ltd TSE:4534
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mochida Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Mochida Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0374+0.528 * 1.0633+0.404 * 1.6945+0.892 * 1.1121+0.115 * 1.0079
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * 0.083477-0.327 * 1.3279
=-1.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was 円36,478 Mil.
Revenue was 円116,951 Mil.
Gross Profit was 円56,260 Mil.
Total Current Assets was 円119,021 Mil.
Total Assets was 円182,720 Mil.
Property, Plant and Equipment(Net PPE) was 円16,302 Mil.
Depreciation, Depletion and Amortization(DDA) was 円2,979 Mil.
Selling, General, & Admin. Expense(SGA) was 円0 Mil.
Total Current Liabilities was 円27,734 Mil.
Long-Term Debt & Capital Lease Obligation was 円10,000 Mil.
Net Income was 円7,903 Mil.
Gross Profit was 円0 Mil.
Cash Flow from Operations was 円-7,350 Mil.
Total Receivables was 円31,617 Mil.
Revenue was 円105,159 Mil.
Gross Profit was 円53,787 Mil.
Total Current Assets was 円119,669 Mil.
Total Assets was 円160,121 Mil.
Property, Plant and Equipment(Net PPE) was 円15,940 Mil.
Depreciation, Depletion and Amortization(DDA) was 円2,940 Mil.
Selling, General, & Admin. Expense(SGA) was 円0 Mil.
Total Current Liabilities was 円24,902 Mil.
Long-Term Debt & Capital Lease Obligation was 円0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(36478 / 116951) / (31617 / 105159)
=0.311908 / 0.300659
=1.0374

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(53787 / 105159) / (56260 / 116951)
=0.511483 / 0.481056
=1.0633

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (119021 + 16302) / 182720) / (1 - (119669 + 15940) / 160121)
=0.259397 / 0.153084
=1.6945

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=116951 / 105159
=1.1121

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2940 / (2940 + 15940)) / (2979 / (2979 + 16302))
=0.15572 / 0.154504
=1.0079

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 116951) / (0 / 105159)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((10000 + 27734) / 182720) / ((0 + 24902) / 160121)
=0.206513 / 0.15552
=1.3279

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(7903 - 0 - -7350) / 182720
=0.083477

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Mochida Pharmaceutical Co has a M-score of -1.75 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.75 mean?
Mochida Pharmaceutical Co (TSE:4534) has a Beneish M-Score of -1.75 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Mochida Pharmaceutical Co and its competitors. According to the industry distribution chart, Mochida Pharmaceutical Co ranks #781 out of 911 companies in the Drug Manufacturers industry, placing it in the top 85.7%.
Is Mochida Pharmaceutical Co's Beneish M-Score too high?
Mochida Pharmaceutical Co's current Beneish M-Score is -1.75. Based on the distribution chart, Mochida Pharmaceutical Co ranks #781 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mochida Pharmaceutical Co has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mochida Pharmaceutical Co's Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mochida Pharmaceutical Co ranks #781 out of 911 companies for Beneish M-Score. This places Mochida Pharmaceutical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Mochida Pharmaceutical Co and its competitors. Mochida Pharmaceutical Co's current Beneish M-Score is -1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mochida Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Mochida Pharmaceutical Co (TSE:4534) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,695.27, compared to a current price of 円3,140.00 — trading 15% below its estimated fair value. The current Beneish M-Score is -1.75. Mochida Pharmaceutical Co's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Mochida Pharmaceutical Co (TSE:4534), the current Beneish M-Score is -1.75 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mochida Pharmaceutical Co (TSE:4534) Overvalued in 2026?

Based on GuruFocus' analysis, Mochida Pharmaceutical Co stock appears to be undervalued. The current stock price of 円3,140.00 is trading 15% below its estimated GF Value™ of 円3,695.27. GuruFocus considers Mochida Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4534:

  • Beneish M-Score: -1.75
  • GF Value™: 円3,695.27 vs. price of 円3,140.00 (15% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the TSE:4534 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mochida Pharmaceutical Co Business Description

Address 1-1 Ichigayahonmuracho, Shinjuku-ku, Tokyo, JPN, 162-0845
Mochida Pharmaceutical Co Ltd is a major drug manufacturing company that operates in the field of medical care through its pharmaceuticals, healthcare products, and medical equipment businesses. The company's pharmaceuticals business aims to develop and market a broad spectrum of innovative new drugs. One of Mochida's main objectives is to maximize the business performance of its drugs after they are developed and released. The company also creates skin care products for the general public, and these are supplied through pharmacies, drugstores, and mail-order sales.
70GF Score

Get the complete analysis for TSE:4534

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,140.00
Price
円3,695.27
GF Value